Hide metadata

dc.date.accessioned2020-08-17T18:24:25Z
dc.date.available2020-08-17T18:24:25Z
dc.date.created2020-07-29T14:49:00Z
dc.date.issued2020
dc.identifier.citationNezvalova-henriksen, Katerina Østerberg, Camilla Tomine Nilsson, Niklas Staven Berge, Vigdis Tho, Ingunn . Y-site physical compatibility of Numeta G13E with drugs frequently used at Neonatal Intensive Care. Pharmaceutics. 2020, 12
dc.identifier.urihttp://hdl.handle.net/10852/78436
dc.description.abstractPreterm neonates require parenteral nutrition (PN) in addition to intravenous drug therapy. Due to limited venous access, drugs are often co-administered with PN via the same lumen. If incompatible, precipitation and emulsion destabilization may occur with the consequent risk of embolism and hyper-immune reactions. Information on intravenous compatibility is scarce. Our aim was to analyse the compatibility of Numeta G13E with paracetamol, vancomycin and fentanyl because of the frequency of their use. A panel of methods was chosen to assess precipitation (sub-visual particle counting, turbidity measurement, Tyndall beam effect and pH measurement) and emulsion destabilization (mean droplet diameter measurement and sub-visual counting of oil droplets, followed by estimation of PFAT5 (percentage of fat residing in globules larger than 5 µm) and pH measurement). Samples in clinically relevant mixing ratios were tested immediately and after 4 h. All samples of drugs mixed with Numeta G13E were compared to unmixed controls. None of the tested drugs precipitated in contact with Numeta G13E, and we did not see any sign of emulsion destabilization when clinically relevant mixing ratios were applied. These results are reassuring. However, when contact time exceeds the established norm, caution in the form of filter utilisation and close inspection is advised.
dc.languageEN
dc.rightsAttribution 4.0 International
dc.rights.urihttps://creativecommons.org/licenses/by/4.0/
dc.titleY-site physical compatibility of Numeta G13E with drugs frequently used at Neonatal Intensive Care
dc.typeJournal article
dc.creator.authorNezvalova-henriksen, Katerina
dc.creator.authorØsterberg, Camilla Tomine
dc.creator.authorNilsson, Niklas
dc.creator.authorStaven Berge, Vigdis
dc.creator.authorTho, Ingunn
cristin.unitcode185,15,23,10
cristin.unitnameGalenisk farmasi og samfunnsfarmasi
cristin.ispublishedtrue
cristin.fulltextoriginal
cristin.qualitycode1
dc.identifier.cristin1820943
dc.identifier.bibliographiccitationinfo:ofi/fmt:kev:mtx:ctx&ctx_ver=Z39.88-2004&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.jtitle=Pharmaceutics&rft.volume=12&rft.spage=&rft.date=2020
dc.identifier.jtitlePharmaceutics
dc.identifier.volume12
dc.identifier.issue7
dc.identifier.doihttps://doi.org/10.3390/pharmaceutics12070677
dc.identifier.urnURN:NBN:no-81544
dc.type.documentTidsskriftartikkel
dc.type.peerreviewedPeer reviewed
dc.source.issn1999-4923
dc.identifier.fulltextFulltext https://www.duo.uio.no/bitstream/handle/10852/78436/1/Nezvalova-Henriksen_2020_Pharmaceutics.pdf
dc.type.versionPublishedVersion
cristin.articleid677


Files in this item

Appears in the following Collection

Hide metadata

Attribution 4.0 International
This item's license is: Attribution 4.0 International